Review
Version 1
Preserved in Portico This version is not peer-reviewed
Biomarkers in IBD: What to Utilize for the Diagnosis?
Version 1
: Received: 8 August 2023 / Approved: 9 August 2023 / Online: 9 August 2023 (10:56:12 CEST)
A peer-reviewed article of this Preprint also exists.
D’Incà, R.; Sturniolo, G. Biomarkers in IBD: What to Utilize for the Diagnosis? Diagnostics 2023, 13, 2931. D’Incà, R.; Sturniolo, G. Biomarkers in IBD: What to Utilize for the Diagnosis? Diagnostics 2023, 13, 2931.
Abstract
The role of biomarkers in the diagnosis of inflammatory bowel disease is not fully characterized. C-reactive protein has a short half-life and elevates quickly after the onset of an inflammatory process, the performance is better in Crohn’s disease than in ulcerative colitis. Erythrocyte sedimentation rate is easy to determine, widely available, and cheap but the long half-life the influence of age, anemia, smoking, and drugs limit its usefulness. Fecal markers have good specificity, but suboptimal accuracy. Microbial antibodies and novel immunological markers show promise but need further evidence before entering clinical practice. Proteomic methods could represent the dawn of a new era of stool protein/peptide biomarker panels able to select patients at risk of inflammatory bowel disease.
Keywords
fecal calprotectin; C reactive protein; p-ANCA; ASCA
Subject
Public Health and Healthcare, Public Health and Health Services
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment
